---
title: "NHS Genomic Medicine Service - Most Suitable Provider Process"
ocid: "ocds-h6vhtk-0565e9"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0565e9"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-0565e9.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-0565e9.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NHS ENGLAND"
published: "2025-10-23"
---

# NHS Genomic Medicine Service - Most Suitable Provider Process

Buyer: NHS ENGLAND  
Current stage: Award  
OCID: ocds-h6vhtk-0565e9

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0565e9)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-0565e9.json)

## Summary

The NHS Genomic Medicine Service (NHS GMS) tender, managed by NHS England, is a significant procurement process aiming to enhance health services across various regions in the United Kingdom. With an estimated total contract value of £5,175,000,000, the services are anticipated to commence on 1st April 2026 and could extend until 31st March 3036. The procurement is segmented into seven distinct Lots, targeting geographic areas like North-West, North-East and Yorkshire, Central and South, with NHS organisations positioned as potential providers. This notice reflects the intention to award under the Provider Selection Regime, highlighting key dates such as the standstill period resulting from the publication on 23rd October 2025 and a deadline for representations by 4th November 2025. The procurement is conducted through a limited procedure, bypassing prior competition calls.

This tender presents substantial opportunities for existing NHS organisations equipped to integrate genomic medicine service functions. It is designed for entities that can demonstrate advanced capabilities in genomic testing, clinical pathways for cancer and rare diseases, and integration of data infrastructure. By enabling expansion in genomic innovation and service delivery, the tender is particularly suited for large-scale NHS suppliers ready to collaborate and leverage existing clinical governance structures. Companies with a focus on integrating new genomic technologies and improving healthcare equity will find immense potential for growth and service improvement in partnership with NHS England through this procurement endeavour.

## Notice

This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.

Pursuant to the NHS GMS contracts, provider are to provide the following functions: 
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital

### Lot Information

Lot 1 - NHS North-West GMS

Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Options: Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period.

Lot 2 - NHS North-East and Yorkshire GMS

Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

Lot 3 - NHS Central and South GMS

Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

Lot 4 - NHS East GMS

Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

Lot 5 - NHS South-West GMS

Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

Lot 6 - NHS North Thames GMS

Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

Lot 7 - NHS South-East GMS

Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

### Procurement Information

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/067976-2025 |
| Notice type | Planning Notice |
| Procurement type | Standard |
| Procurement category | Services |
| Procurement method | Limited |
| Procurement method details | Award procedure without prior publication of a call for competition |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Planning, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 23 Oct 2025 |
| Submission deadline | Not specified |
| Future notice date | 17 Sep 2025 |
| Award date | 20 Oct 2025 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £3,850,000,000 |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £5,175,000,000 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND |
| Locality | LEEDS |
| Post town | Leeds |
| Postcode | LS1 4AP |
| Country | England |
| ITL 1 | TLE Yorkshire and The Humber |
| ITL 2 | TLE4 West Yorkshire |
| ITL 3 | TLE42 Leeds |
| Local authority | Leeds |
| Electoral ward | Hunslet & Riverside |
| Westminster constituency | Leeds South |
| Delivery location | TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England) |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 7 |
| Supplier names | BIRMINGHAM WOMEN’S AND CHILDREN’S NHS FOUNDATION TRUST; CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST; GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST; GUY'S AND ST THOMAS' NHS FOUNDATION TRUST; MANCHESTER UNIVERSITY NHS FOUNDATION TRUST; NORTH BRISTOL NHS TRUST; THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST |

## CPV Codes

### Divisions

- 85 - Health and social work services

### Codes

- 85100000 - Health services

## Release History

- 23 Oct 2025 at 16:00 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/067976-2025
- 24 Jul 2025 at 16:52 - Planning - Planning Notice - https://www.find-tender.service.gov.uk/Notice/042969-2025

## Notice URLs

- https://health-family.force.com/s/Welcome
- https://www.ardengemcsu.nhs.uk/
- https://www.england.nhs.uk//

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0565e9. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-0565e9.json.